Floatz Rating
CC44/100
Confidence
Indicative
Sponsor
Medical College of Wisconsin
Modality
antibody_drug_conjugate
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05270057CT.gov Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies | — | Active Not Recruiting | — | — | — |
NCT02669017CT.gov Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Burkitt Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Loncastuximab Tesirine (this asset) | Medical College of Wisconsin | P1 | CC · 44 |
| Nivestim | Fred Hutchinson Cancer Center | P4 | BBB |
| Vincristine Sulfate | AIDS Malignancy Consortium | P2 | BBB |
| Vindesine | PETHEMA Foundation | P4 | BBB |
| Cyclophosphamide | AIDS Malignancy Consortium | P4 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BBB |
| Cytarabine | AIDS Malignancy Consortium | P4 | BBB |
| Romidepsin | M.D. Anderson Cancer Center | P2 | BBB |
| Adriamycin | AIDS Malignancy Consortium | P4 | BBB |
+42 more in the Burkitt Lymphoma cohort
Other indications for Loncastuximab Tesirine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Non-Hodgkin Lymphoma | — | P2/3 | B · 61 |
| Marginal Zone Lymphoma | — | P2 | CCC · 55 |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | P3 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Loncastuximab Tesirine in Burkitt Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/loncastuximab-tesirine-burkitt-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →